Switzerland’s Agency for Therapeutic Products (Swissmedic) has awarded PharmaMar’s Aplidin orphan drug status to treat patients with multiple myeloma, following a similar designation by the U.S. Food…
News
MYELOMA
One World Cannabis to Test Mice in Pursuit of Therapies Targeting Multiple Myeloma Cancer Cells
Israel’s One World Cannabis (OWC) says it’s moving forward to mouse models to test its unique formula of cannabinoid-based therapies targeting cancer cells. This decision followed promising results…
Janssen’s Darzalex (daratumumab) received full approval by the European Commission (EC) for use in treating adult patients with multiple myeloma who have received at least…
GlycoMimetics’ GMI-1271 restored the punch of the myeloma treatment Velcade (bortezomib) in mice, which should rekindle hope in patients who failed to respond to…
Multiple myeloma patients who received at least three prior lines of therapy and whose cancer expresses the CD33 molecule may enroll in the recently opened…
Janssen Biotech will discuss at a Chicago cancer conference the effectiveness of new multiple myeloma treatment combinations that include its therapy Darzalex (daratumumab). The…
Don Wright, the 76-year-old marathon runner who recently reached his goal of running 100 marathons after being diagnosed with multiple myeloma, ran Philadelphia’s Miles for…
Patients with multiple myeloma soon may be diagnosed and followed solely with the use of a blood sample, avoiding the painful process of collecting a…
The small molecule immunomodulatory drug tasquinimod has been designated an orphan drug by the U.S. Food and Drug Administration (FDA) for the treatment of multiple…
Syrian-born hematologist-oncologist Ahmad Samer Al-Homsi, MD, MBA, will lead an innovative program at NYU Langone’s Perlmutter Cancer Center for treating blood cancers, including multiple…
Recent Posts
- Daraxonrasib may offer new hope in previously treated pancreatic cancer
- A tribute to the nurse who remembered my name
- Plixorafenib given FDA breakthrough status for high-grade gliomas
- New Keytruda regimen OK’d in EU for hard-to-treat gynecological cancers
- FDA to review glioma imaging agent, sets September decision date
